NeuroPace, Inc. (NPCE)

Over the past six months, NeuroPace's stock has experienced several notable events. The company reported its fourth quarter and full year 2025 financial results in early March 2026, and is scheduled to report its first quarter 2026 financial results on May 12, 2026. In January 2026, NeuroPace reported preliminary unaudited results for Q4 and FY 2025, with total revenue of approximately $26.6 million for Q4 2025 and $100 million for FY 2025. NeuroPace highlighted expanding clinical evidence leadership with published 3-year Post-Approval Study (PAS) results and a NAUTILUS Presentation at AAN 2026 in April 2026. A Premarket Approval Supplement (PMA-S) for an expanded IGE indication was filed in December 2025, with an FDA decision expected around June 15, 2026. NeuroPace presented at the Leerink Global Healthcare Conference in March 2026 and the 25th Annual Needham Virtual Healthcare Conference in April 2026. In April 2025, the company announced it would terminate its distribution relationship for SEEG products to focus on its core RNS System. The stock has gained 59.2% over the past 12 months and hit a new 52-week high in May 2026. Analysts have a "Moderate Buy" consensus rating with an average target price of $18.67.

The provided information does not explicitly detail demand seasonality for NeuroPace's products and services. The company's revenue growth is driven by the adoption of the RNS System in Comprehensive Epilepsy Centers (CECs). The company's strategic focus on expanding access to RNS therapy in existing and new indications suggests a continuous effort to drive demand rather than a reliance on seasonal fluctuations. The sales of its products to hospital facilities would likely be influenced by patient diagnoses and treatment plans rather than typical seasonal consumer buying patterns.

NeuroPace, Inc., based in Mountain View, California, is a commercial-stage medical device company focused on reducing seizures in individuals with epilepsy. The company operates in the Healthcare sector, specifically within the Healthcare Equipment & Supplies/Medical Device industry. Its primary product is the RNS System, the first FDA-approved brain-responsive neuromodulation system, which delivers personalized, real-time treatment for drug-resistant focal epilepsy. The RNS System includes the neurostimulator, leads, and a Patient Remote Monitor. NeuroPace also provides a Physician Tablet and a Patient Data Management System (PDMS). The nSight Platform offers clinicians personalized patient reports and programming suggestions. NeuroPace previously had a distribution relationship for Stereo EEG (SEEG) products, which it began winding down in the fourth quarter of 2025 to refocus on its core RNS System.

NeuroPace, Inc. is headquartered in Mountain View, California, and primarily operates in the United States market. The company sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures.

NeuroPace's brand reputation in the past year appears to be positive, largely driven by its innovative RNS System and expanding clinical evidence. The company is recognized as a leader in brain-responsive neuromodulation. The publication of 3-year Post-Approval Study (PAS) results and the RNS System's Breakthrough Device Designation by the FDA for the IGE indication underscore its potential to address significant unmet clinical needs. Analysts have a generally positive outlook, with a consensus "Moderate Buy" rating. The company's focus on AI product development and clinical expansion positions it for future growth and innovation. No significant negative events impacting reputation were found in the provided snippets for the past year.

NeuroPace, Inc. is primarily owned by institutional shareholders, who hold 78.12% of the stock, and NeuroPace insiders, owning 83.99%. Retail investors hold 0.00%. Major institutional owners include Accelmed Partners II LP, OrbiMed Private Investments VI, LP, Polar Capital Holdings Plc, Soleus Capital Management, L.P., BlackRock, Inc., and The Vanguard Group, Inc. Key individual insiders include URI Geiger and Greg Shaw Garfield.